Incyte Corporation (BMV:INCY)

Mexico flag Mexico · Delayed Price · Currency is MXN
1,849.09
0.00 (0.00%)
At close: Dec 3, 2025
24.43%
Market Cap 359.71B
Revenue (ttm) 88.28B
Net Income (ttm) 21.80B
Shares Out n/a
EPS (ttm) 108.27
PE Ratio 16.50
Forward PE 11.96
Dividend n/a
Ex-Dividend Date n/a
Volume 300
Average Volume 1,600
Open 1,849.09
Previous Close n/a
Day's Range 1,849.09 - 1,849.09
52-Week Range 1,180.69 - 1,959.00
Beta n/a
RSI 71.08
Earnings Date Feb 3, 2026

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhib... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1991
Employees 2,617
Stock Exchange Mexican Stock Exchange
Ticker Symbol INCY
Full Company Profile

Financial Performance

In 2024, Incyte's revenue was $4.24 billion, an increase of 14.76% compared to the previous year's $3.70 billion. Earnings were $32.62 million, a decrease of -94.54%.

Financial numbers in USD Financial Statements

News

There is no news available yet.